Abstract Multiple Sclerosis (MS) is one of the most common neurological disorders diagnosed in young adults. there are no current cures for the disease or its underlying causes, some drugs have been developed that can decrease or delay disease progression. Fingolimod is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). It approximately halves the rate of relapse ...

El fingolimod es un tratamiento modificador de la enfermedad ampliamente utilizado en Esclerosis Mu?ltiple Remitente- Recurrente. fa?rmaco bloquea salida los linfocitos ganglios linfa?ticos, con consiguiente linfopenia secundaria. Esto aumenta el riesgo infecciones y tumores cuta?neos no melanoci?ticos. Presentamos caso paciente que sufrio? posteriormente carcinoma ce?lulas Merkel. Realizamos u...

INTRODUCTION Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed t...

OBJECTIVES Previous systematic reviews and meta-analyses of treatments in relapsing-remitting multiple sclerosis (RRMS) derived their findings from either placebo-controlled studies only or separately from head-to-head and comparative studies. The purpose of this study is to compare annualized relapse rates (ARR) of fingolimod versus all of the commonly used first-line treatments in RRMS using ...

MULTIPLE SCLEROSIS MSJ JOURNAL Multiple sclerosis (MS) is an inflammatory disease, and the relapsing–remitting form of MS (RRMS) is widely considered to be the most inflammatory phenotype of MS. There are currently eight approved therapies for patients with RRMS. Not surprisingly, all of these medications are anti-inflammatory. The mechanisms of action of agents that were approved in the 1990s ...

BACKGROUND AND PURPOSE Growing evidence supports that the immunomodulatory drug fingolimod is protective in stroke. Fingolimod binds to 4 of 5 sphingosine-1-phosphate (S1P) receptors and, among other actions, it induces lymphopenia. In this study, we investigated whether a selective S1P1 agonist is protective in experimental stroke. METHODS Drug selectivity was studied in vitro in cells overe...

BACKGROUND Cerebral gray matter (GM) atrophy has clinical relevance in multiple sclerosis (MS). Fingolimod has known efficacy on clinical and conventional MRI findings in MS; the effect on GM is unknown. OBJECTIVE To explore fingolimod's treatment effect on cerebral GM atrophy over two years in patients with relapsing forms of MS. DESIGN/METHODS Patients starting fingolimod [n=24, age (mean...

There are currently three oral medications approved for the treatment of multiple sclerosis (MS). Two of these medications, Fingolimod, and Teriflunomide, are considered to be anti-inflammatory agents, while dimethyl fumarate (DMF) is thought to trigger a robust antioxidant response, protecting vulnerable cells during an MS attack. We previously proposed that epsilon toxin from the gut bacteriu...